Develops biosimilars for autoimmune and eye diseases.
Dec 2025Revenue $586M/yrExpenses $508M/yr
Reached break-even Oct 2024
Figures by year
When did Alvotech become profitable?
Its revenue passed its expenses in Oct 2024. In the 12 months to Dec 2025, revenue was $586M and expenses $508M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $586M | $508M | $78.2M |
| Dec 2024 | $490M | $420M | $69.6M |
| Dec 2023 | $91.4M | $446M | −$355M |
| Dec 2022 | $83.0M | $429M | −$346M |
| Dec 2021 | $36.8M | $272M | −$235M |
| Dec 2020 | $66.6M | $204M | −$138M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.